BM-MSC Accelerates Acute Stroke Recovery

BM-MSC Accelerates Acute Stroke Recovery In a Randomized Placebo-controlled Clinical Phase II/III Study

MI Norlinah¹ , HJ Tan¹ , SP Chin³ , ZK Law¹ , I Nor Azimah² , NA Nur’Ain³ , SK Cheong^3,4, SAW Fadilah^1,2

¹ Department of Medicine, ² Cell Therapy Center, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, ³ Cytopeutics, Malaysia, ⁴ Tunku Abdul Rahman University, Malaysia.

Our results showed that patients with acute stroke who received BM-MSC infusion benefited from significant improvement in clinical disability and functional outcome as early as 6 weeks of follow-up. The benefit was sustained up to 12 months follow-up and may potentially reduce mortality from sepsis.

Figure 1: The mean of NIHSS score at baseline and after (6 weeks, 3, 6, 9 and 12 months) BM-MSC infusion. *One-way ANOVA. Scheffe’s post-hoc multiple comparison was used to test the difference between each visit (p<0.05).

Figure 2: The mean of Barthel Index score at baseline and after (6 weeks, 3, 6, 9 and 12 months) BM-MSC infusion. *One-way ANOVA Scheffe’s post-hoc multiple comparison was used to test the difference between each visit (p=0.04).